Navigation Links
Edwards Lifesciences Opens New Singapore Heart Valve Facility
Date:5/22/2008

SINGAPORE, May 22 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, today announced the opening of its new heart valve manufacturing facility in Changi North Crescent, Singapore. The state-of-the-art facility produces Edwards' world-leading Carpentier-Edwards PERIMOUNT tissue heart valve replacements, and also serves as the headquarters for Edwards' Asia-Pacific operations, one of the company's fastest-growing regions.

"Edwards' new Singapore facility was developed to meet the global demands for our technologically advanced tissue heart valve replacement products," said Donald E. Bobo, Jr., Edwards' corporate vice president, heart valve therapy. "The opening coincides with our 50th anniversary of partnering with clinicians to develop life-saving innovations and we look forward to serving more patients around the world through our heart valve operations in the United States, Switzerland, and now, Singapore."

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 years of partnering with clinicians to develop life-saving innovations. The company's global brands, which are sold in approximately 100 countries, include CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.


'/>"/>
SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008
2. Edwards Lifesciences to Webcast Annual Stockholders Meeting
3. Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance
4. Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
5. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
6. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
7. Edwards Lifesciences Announces Organizational Changes
8. Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008
10. Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
11. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017  ArmaGen, Inc., a privately held biotechnology ... severe neurological disorders, today reported preliminary evidence of ... company,s investigational therapy for the treatment of Hurler ... I, or MPS I). The initial results from ... today at the 13 th annual WORLD ...
(Date:2/16/2017)... -- UCHealth ( Aurora, Colorado ) becomes ... patient management. In addition to optimizing care coordination for ... lung, UCHealth looks to improve provider workflow by decreasing ... Stephanie Brown, RN , Thoracic Nurse Navigator, says, ... Excel spreadsheet, which was extremely arduous and susceptible to ...
(Date:2/16/2017)...  Rhythm, a biopharmaceutical company developing peptide ... in life-threatening metabolic disorders, today announced the ... of financing with existing investors including Deerfield ... Associates, Pfizer Venture Investments, Third Rock Ventures, ... Rhythm will use the proceeds to advance ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. („TRIANNI") ... Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung der ... führenden Plattform für die Entdeckung monoklonaler Antikörper. ... neuartiges chimäres Gensegmentdesign aus, das Janssen den ... Antikörpern bietet und das für die schelle Isolierung ...
Breaking Biology Technology:
(Date:2/3/2017)... 3, 2017 A new independent identity strategy ... LLP (IdSP) . Designed to fill a critical niche ... market, founding partners Mark Crego and ... just in identity expertise that span federal governments, the ... The Crego-Kephart combined expertise has a common theme born ...
(Date:2/2/2017)... -- EyeLock LLC, a market leader of iris-based identity authentication ... You Should Know About Biometrics in the Cloud ."  ... a growing concern. In traditional schemes, cryptography is used ... schemes such as username/password suffer from inherent weaknesses. ... elegant solution to the problem of high-security user authentication. ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent market research, business ... new report, Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027 ... ... Revenues of ... for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine vision, force sensing ...
Breaking Biology News(10 mins):